|
Christian Medical College Ludhiana Society (Regd.)Ludhiana Punjab India,
Hospitals & Health Networks, Hospitals for a Healthy Environment, LifeCare
Hospital
|
|
|
| |
|
ZD4054 in Hormone
Resistant Prostate Cancer |
|
Protocol 1 |
|
A
Phase III, Randomized, Double-blind Study to Assess
the Efficacy and Safety of 15 mg ZD4054 versus
Placebo, both with Best Supportive Care, in Patients
with Hormone-resistant Prostate Cancer and Bone
Metastasis who are Pain Free or Mildly Symptomatic. |
|
Protocol 2 |
|
A
Phase III, Randomized, Double-blind,
Placebo-controlled Study to Assess the Efficacy and
Safety of 15 mg ZD4054 in combination with Docetaxel
in comparison with Docetaxel in Patients with
Metastatic Hormone-resistant Prostate Cancer. |
|
Protocol 3 |
|
A
Phase III, Randomized, Double-blind Study to Assess
the Efficacy and Safety of Once-daily Orally
Administered ZD4054 15mg in Non-metastatic Hormone
Resistant Prostate Cancer Patients.
|
Principal
Investigator: Dr Kim Mammen
Co-Investigator: Dr Rajesh Chakraborty
|
An Epidemiological
Study on Prostate Cancer
Sponsored
by Cancer of Prostate Endeavor (COPE India) and ICMR.
Principal investigator: Dr Kim Mammen. |
|
Whom to contact?
Dr. Kim Mammen
Professor and Head of Urology, Dy Director CMCH
Department Of Urology
CMC & Hospital, Ludhiana.
Tel: +161-502 6999 (Hospital)
E-mail:
kjmammen@gmail.com
|
|
|
|
|
|
|
|
|
